Project Grant R43CA281460
Award Date 9/22/23
Completion Date 8/31/24
Dollars Obligated $400K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to support research by Oncotab, Inc. on optimized targeted radiotherapy for pancreatic cancer. The key objectives are to develop a tumor-specific antibody (HTAB004) and a tandem single-chain variable fragment (scFv) targeting agent labeled with alpha and beta particle-emitting radioisotopes. This research aims to overcome the challenge of the desmoplastic stroma in pancreatic...
- This $147,486 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the role of transcription factor ATF4 in the early stages of pancreatic ductal adenocarcinoma (PDAC) development. The research aims to elucidate ATF4's regulatory functions in two critical early steps of PDAC - acinar to ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) formation. Through novel experimental approaches, the project...
- This SBIR Phase I grant, awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), provides $400,000 to Canget Biotekpharma LLC to perform critical pre-clinical studies and regulatory filings to enable first-in-human clinical trials of their novel cancer drug candidate FL118 for advanced pancreatic cancer. Specifically, the project aims to: (1) conduct non-GLP and GLP toxicology and toxicokinetic studies of the clinically compatible FL118 formulation; and (2) author and...
- The National Cancer Institute (NCI) awarded a $137,995 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Dana-Farber Cancer Institute, Inc. (DFCI) to develop an innovative drug delivery platform for pancreatic cancer treatment. The project aims to engineer an implantable hydrogel that encapsulates drug-producing bacteria, creating an "engineered living material" (ELM) for localized, dynamic, and tunable therapeutic delivery to pancreatic ductal adenocarcinoma...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,970 to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle formulation designed to improve the delivery and efficacy of combination chemotherapy for advanced pancreatic cancer. The key product being developed under this award is DUO-207, which combines a polymer-conjugated gemcitabine and paclitaxel in a single 14nm nanoparticle. This novel formulation...
- This federal Project Grant award for $778,873, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research conducted by Cold Spring Harbor Laboratory (CSHL) to investigate the role of the enzyme SOAT1 as a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC). The key objectives of this multi-year (Jun 2025 - May 2030) research project are to use mouse and patient-derived PDAC organoid models to: 1) evaluate the...
- This $1,377,000 Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) aims to develop a novel oncolytic virus platform called VMG for the treatment of pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this 3-year project include: Evaluating the VMG oncolytic virus vector's ability to selectively target and destroy PDAC tumor cells while sparing normal tissues, through expression of enzymes to break...
- This $642,755 Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), supports research by The Institute for Cancer Research (ICR) to investigate the role of the protein Anoctamin 6 (ANO6) in disrupting the trogocytosis process that enables cancer-associated fibroblasts to transfer lipids to pancreatic ductal adenocarcinoma (PDAC) tumor cells. The research aims to elucidate how ANO6 activity is regulated in the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $338,828 to Bioplatinum Technologies LLC to study the effects of new platinum anticancer drugs in pancreatic cancer. The project aims to exploit the high levels of chondroitin-4-sulfate (C4S) glycosaminoglycans in pancreatic tumors to enhance the delivery and efficacy of the polynuclear platinum complex (PPC) drug triplatin. The research will evaluate triplatin as a potential...
- The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...